Cargando…
Pharmacy Compounding Primer for Physicians: Prescriber Beware
Since the development of federal standards for drug approval, the practice of medicine has historically involved the compounding of medications based on a physician’s determination that a US FDA-approved product either did not exist, or could not be used for medical reasons. Today, prescriptions for...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695671/ https://www.ncbi.nlm.nih.gov/pubmed/23039281 http://dx.doi.org/10.2165/11640850-000000000-00000 |
_version_ | 1782274995741786112 |
---|---|
author | Sellers, Sarah Utian, Wulf H. |
author_facet | Sellers, Sarah Utian, Wulf H. |
author_sort | Sellers, Sarah |
collection | PubMed |
description | Since the development of federal standards for drug approval, the practice of medicine has historically involved the compounding of medications based on a physician’s determination that a US FDA-approved product either did not exist, or could not be used for medical reasons. Today, prescriptions for non-FDA-approved compounded drugs may be driven by fanciful and largely unregulated pharmacy advertisements to physicians and patients and/or payer reimbursement policies, thus placing prescribers in the backseat for clinical decision making. This article outlines essential differences between FDA-approved drugs and compounded drugs and reasserts the primary medical role of physicians for determining what medical circumstances may necessitate treatment with non-FDA-approved products. In addition, liability concerns when prescribing non-FDA-approved drugs are discussed. While representing a US perspective, underlying principles apply globally in the setting of magistral and extemporaneous formulations produced outside national regulatory frameworks. |
format | Online Article Text |
id | pubmed-3695671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-36956712013-07-18 Pharmacy Compounding Primer for Physicians: Prescriber Beware Sellers, Sarah Utian, Wulf H. Drugs Current Opinion Since the development of federal standards for drug approval, the practice of medicine has historically involved the compounding of medications based on a physician’s determination that a US FDA-approved product either did not exist, or could not be used for medical reasons. Today, prescriptions for non-FDA-approved compounded drugs may be driven by fanciful and largely unregulated pharmacy advertisements to physicians and patients and/or payer reimbursement policies, thus placing prescribers in the backseat for clinical decision making. This article outlines essential differences between FDA-approved drugs and compounded drugs and reasserts the primary medical role of physicians for determining what medical circumstances may necessitate treatment with non-FDA-approved products. In addition, liability concerns when prescribing non-FDA-approved drugs are discussed. While representing a US perspective, underlying principles apply globally in the setting of magistral and extemporaneous formulations produced outside national regulatory frameworks. Springer International Publishing 2012-12-25 2012 /pmc/articles/PMC3695671/ /pubmed/23039281 http://dx.doi.org/10.2165/11640850-000000000-00000 Text en © Springer International Publishing AG 2012 |
spellingShingle | Current Opinion Sellers, Sarah Utian, Wulf H. Pharmacy Compounding Primer for Physicians: Prescriber Beware |
title | Pharmacy Compounding Primer for Physicians: Prescriber Beware |
title_full | Pharmacy Compounding Primer for Physicians: Prescriber Beware |
title_fullStr | Pharmacy Compounding Primer for Physicians: Prescriber Beware |
title_full_unstemmed | Pharmacy Compounding Primer for Physicians: Prescriber Beware |
title_short | Pharmacy Compounding Primer for Physicians: Prescriber Beware |
title_sort | pharmacy compounding primer for physicians: prescriber beware |
topic | Current Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695671/ https://www.ncbi.nlm.nih.gov/pubmed/23039281 http://dx.doi.org/10.2165/11640850-000000000-00000 |
work_keys_str_mv | AT sellerssarah pharmacycompoundingprimerforphysiciansprescriberbeware AT utianwulfh pharmacycompoundingprimerforphysiciansprescriberbeware |